Riluzole activates TRPC5 channels independently of PLC activity

British Journal of Pharmacology

Volumn 171, Issue 1, 2014, Pages 158-170

  Richter, Julia M ^a   Schaefer, Michael ^a   Hill, Kerstin ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

calcium imaging; patch clamp electrophysiology; riluzole; TRPC5

Indexed keywords

CALCIUM; GUANINE NUCLEOTIDE BINDING PROTEIN; LANTHANUM; MUTANT PROTEIN; NATURAL PRODUCT; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; RILUZOLE; TRANSIENT RECEPTOR POTENTIAL CHANNEL 5;

ARTICLE; BINDING SITE; BIOPHYSICS; CALCIUM CELL LEVEL; CELL STRAIN; CELL STRAIN HEK293; CELL STRAIN U 87; CONTROLLED STUDY; CYTOSOL; DRUG APPROVAL; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; ELECTROPHYSIOLOGY; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

CALCIUM IMAGING; PATCH CLAMP ELECTROPHYSIOLOGY; RILUZOLE; TRPC5;

ANIMALS; BINDING SITES; CALCIUM SIGNALING; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEINS; HEK293 CELLS; HUMANS; ION CHANNEL GATING; LANTHANUM; MEMBRANE POTENTIALS; MICE; MICROSCOPY, FLUORESCENCE; MICROSCOPY, VIDEO; MOLECULAR SEQUENCE DATA; MUTATION; RILUZOLE; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TRPC CATION CHANNELS; TYPE C PHOSPHOLIPASES;

EID: 84890280718     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12436     Document Type: Article

References (58)

1. Alexander SPH, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1867.
2. Bahnasi YM, Wright HM, Milligan CJ, Dedman AM, Zeng F, Hopkins PM, et al. (2008). Modulation of TRPC5 cation channels by halothane, chloroform and propofol. Br J Pharmacol 153: 1505-1512.
3. Beech DJ, Muraki K, Flemming R, (2004). Non-selective cationic channels of smooth muscle and the mammalian homologues of Drosophila TRP. J Physiol 559: 685-706.
4. Bellingham MC, (2011). A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther 17: 4-31.
5. Bezzerides VJ, Ramsey IS, Kotecha S, Greka A, Clapham DE, (2004). Rapid vesicular translocation and insertion of TRP channels. Nat Cell Biol 6: 709-720.
6. Blair NT, Kaczmarek JS, Clapham DE, (2009). Intracellular calcium strongly potentiates agonist-activated TRPC5 channels. J Gen Physiol 133: 525-546.
7. Cheah BC, Vucic S, Krishnan AV, Kiernan MC, (2010). Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem 17: 1942-1959.
8. Clapham DE, (2003). TRP channels as cellular sensors. Nature 426: 517-524.
9. Colovic M, Zennaro E, Caccia S, (2004). Liquid chromatographic assay for riluzole in mouse plasma and central nervous system tissues. J Chromatogr B Analyt Technol Biomed Life Sci 803: 305-309.
10. Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z, et al. (2007). The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32: 793-802.
11. Duprat F, Lesage F, Patel AJ, Fink M, Romey G, Lazdunski M, (2000). The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK. Mol Pharmacol 57: 906-912.
12. Flemming PK, Dedman AM, Xu SZ, Li J, Zeng F, Naylor J, et al. (2006). Sensing of lysophospholipids by TRPC5 calcium channel. J Biol Chem 281: 4977-4982.
13. Fowler MA, Sidiropoulou K, Ozkan ED, Phillips CW, Cooper DC, (2007). Corticolimbic expression of TRPC4 and TRPC5 channels in the rodent brain. PLoS ONE 2: e573.
14. Fruhwald J, Camacho LJ, Dembla S, Mannebach S, Lis A, Drews A, et al. (2012). Alternative splicing of a protein domain indispensable for function of transient receptor potential melastatin 3 (TRPM3) ion channels. J Biol Chem 287: 36663-36672.
15. Goel M, Sinkins WG, Schilling WP, (2002). Selective association of TRPC channel subunits in rat brain synaptosomes. J Biol Chem 277: 48303-48310.
16. Grant P, Song JY, Swedo SE, (2010). Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 20: 309-315.
17. Greka A, Navarro B, Oancea E, Duggan A, Clapham DE, (2003). TRPC5 is a regulator of hippocampal neurite length and growth cone morphology. Nat Neurosci 6: 837-845.
18. Hofmann T, Schaefer M, Schultz G, Gudermann T, (2002). Subunit composition of mammalian transient receptor potential channels in living cells. Proc Natl Acad Sci U S A 99: 7461-7466.
19. Huang CS, Song JH, Nagata K, Yeh JZ, Narahashi T, (1997). Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons. J Pharmacol Exp Ther 282: 1280-1290.
20. Hui H, McHugh D, Hannan M, Zeng F, Xu SZ, Khan SU, et al. (2006). Calcium-sensing mechanism in TRPC5 channels contributing to retardation of neurite outgrowth. J Physiol 572: 165-172.
21. Jung S, Muhle A, Schaefer M, Strotmann R, Schultz G, Plant TD, (2003). Lanthanides potentiate TRPC5 currents by an action at extracellular sites close to the pore mouth. J Biol Chem 278: 3562-3571.
22. Kawabata A, Saifeddine M, Al-Ani B, Hollenberg MD, (1997). Protease-activated receptors: development of agonists selective for receptors triggered by either thrombin (PAR1) or trypsin (PAR2). Proc West Pharmacol Soc 40: 49-51.
23. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, et al. (1996). A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology 47: S242-S250.
24. Lee HJ, Wall BA, Wangari-Talbot J, Shin SS, Rosenberg S, Chan JL, et al. (2011). Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res 17: 7080-7092.
25. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, et al. (2007). Genome-wide atlas of gene expression in the adult mouse brain. Nature 445: 168-176.
26. 2+-controlled competitive diacylglycerol binding of protein kinase C isoenzymes in living cells. J Cell Biol 159: 291-302.
27. Ma X, Cai Y, He D, Zou C, Zhang P, Lo CY, et al. (2012). Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells. Proc Natl Acad Sci U S A 109: 16282-16287.
28. Majeed Y, Bahnasi Y, Seymour VA, Wilson LA, Milligan CJ, Agarwal AK, et al. (2011). Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels. Mol Pharmacol 79: 1023-1030.
29. Mohammadi B, Lang N, Dengler R, Bufler J, (2002). Interaction of high concentrations of riluzole with recombinant skeletal muscle sodium channels and adult-type nicotinic receptor channels. Muscle Nerve 26: 539-545.
30. Munsch T, Freichel M, Flockerzi V, Pape HC, (2003). Contribution of transient receptor potential channels to the control of GABA release from dendrites. Proc Natl Acad Sci U S A 100: 16065-16070.
31. Norenberg W, Sobottka H, Hempel C, Plotz T, Fischer W, Schmalzing G, et al. (2012). Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors. Br J Pharmacol 167: 48-66.
32. Otsuguro K, Tang J, Tang Y, Xiao R, Freichel M, Tsvilovskyy V, et al. (2008). Isoform-specific inhibition of TRPC4 channel by phosphatidylinositol 4,5-bisphosphate. J Biol Chem 283: 10026-10036.
33. Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G, (2008). Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 22: 761-786.
34. Putney JW, Jr, (2004). The enigmatic TRPCs: multifunctional cation channels. Trends Cell Biol 14: 282-286.
35. Riccio A, Medhurst AD, Mattei C, Kelsell RE, Calver AR, Randall AD, et al. (2002). mRNA distribution analysis of human TRPC family in CNS and peripheral tissues. Brain Res Mol Brain Res 109: 95-104.
36. Riccio A, Li Y, Moon J, Kim KS, Smith KS, Rudolph U, et al. (2009). Essential role for TRPC5 in amygdala function and fear-related behavior. Cell 137: 761-772.
37. Schachter JB, Sromek SM, Nicholas RA, Harden TK, (1997). HEK293 human embryonic kidney cells endogenously express the P2Y1 and P2Y2 receptors. Neuropharmacology 36: 1181-1187.
38. Schaefer M, Plant TD, Obukhov AG, Hofmann T, Gudermann T, Schultz G, (2000). Receptor-mediated regulation of the nonselective cation channels TRPC4 and TRPC5. J Biol Chem 275: 17517-17526.
39. Schaefer M, Albrecht N, Hofmann T, Gudermann T, Schultz G, (2001). Diffusion-limited translocation mechanism of protein kinase C isotypes. FASEB J 15: 1634-1636.
40. Schuster JE, Fu R, Siddique T, Heckman CJ, (2012). Effect of prolonged riluzole exposure on cultured motoneurons in a mouse model of ALS. J Neurophysiol 107: 484-492.
41. Semtner M, Schaefer M, Pinkenburg O, Plant TD, (2007). Potentiation of TRPC5 by protons. J Biol Chem 282: 33868-33878.
42. Song JH, Huang CS, Nagata K, Yeh JZ, Narahashi T, (1997). Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther 282: 707-714.
43. Storch U, Forst AL, Philipp M, Gudermann T, Schnitzler M, (2012). Transient receptor potential channel 1 (TRPC1) reduces calcium permeability in heteromeric channel complexes. J Biol Chem 287: 3530-3540.
44. Strubing C, Krapivinsky G, Krapivinsky L, Clapham DE, (2001). TRPC1 and TRPC5 form a novel cation channel in mammalian brain. Neuron 29: 645-655.
45. Strubing C, Krapivinsky G, Krapivinsky L, Clapham DE, (2003). Formation of novel TRPC channels by complex subunit interactions in embryonic brain. J Biol Chem 278: 39014-39019.
46. 2+). Biochem Biophys Res Commun 393: 50-54.
47. Sung TS, Jeon JP, Kim BJ, Hong C, Kim SY, Kim J, et al. (2011). Molecular determinants of PKA-dependent inhibition of TRPC5 channel. Am J Physiol Cell Physiol 301: 823-832.
48. 2+ transport. Mol Pharmacol 75: 608-616.
49. Urban N, Hill K, Wang L, Kuebler WM, Schaefer M, (2012). Novel pharmacological TRPC inhibitors block hypoxia-induced vasoconstriction. Cell Calcium 51: 194-206.
50. Wang B, Li W, Meng X, Zou F, (2009). Hypoxia up-regulates vascular endothelial growth factor in U-87 MG cells: involvement of TRPC1. Neurosci Lett 459: 132-136.
51. + current and activation of BKCa channels in cultured differentiated human skeletal muscle cells. Life Sci 82: 11-20.
52. Wong CO, Huang Y, Yao X, (2010). Genistein potentiates activity of the cation channel TRPC5 independently of tyrosine kinases. Br J Pharmacol 159: 1486-1496.
53. Wu G, Lu ZH, Obukhov AG, Nowycky MC, Ledeen RW, (2007). Induction of calcium influx through TRPC5 channels by cross-linking of GM1 ganglioside associated with alpha5beta1 integrin initiates neurite outgrowth. J Neurosci 27: 7447-7458.
54. Wu SN, Li HF, (1999). Characterization of riluzole-induced stimulation of large-conductance calcium-activated potassium channels in rat pituitary GH3 cells. J Investig Med 47: 484-495.
55. Xu SZ, Zeng F, Boulay G, Grimm C, Harteneck C, Beech DJ, (2005). Block of TRPC5 channels by 2-aminoethoxydiphenyl borate: a differential, extracellular and voltage-dependent effect. Br J Pharmacol 145: 405-414.
56. Yamada H, Wakamori M, Hara Y, Takahashi Y, Konishi K, Imoto K, et al. (2000). Spontaneous single-channel activity of neuronal TRP5 channel recombinantly expressed in HEK293 cells. Neurosci Lett 285: 111-114.
57. 2+ entry. J Biol Chem 273: 133-142.
58. Zimmermann K, Lennerz JK, Hein A, Link AS, Kaczmarek JS, Delling M, et al. (2011). Transient receptor potential cation channel, subfamily C, member 5 (TRPC5) is a cold-transducer in the peripheral nervous system. Proc Natl Acad Sci U S A 108: 18114-18119.